Psychemedics Corporation Logo

Psychemedics Corporation

PMD

(1.5)
Stock Price

2,67 USD

-45.08% ROA

-49.63% ROE

-2.95x PER

Market Cap.

13.459.356,00 USD

32.54% DER

0% Yield

-14.78% NPM

Psychemedics Corporation Stock Analysis

Psychemedics Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Psychemedics Corporation Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (33%), which means it has a small amount of debt compared to the ownership it holds

2 Dividend

Investors can trust the company's impressive dividend track record, consistently distributing dividends over the past five years, showcasing a strong commitment to rewarding shareholders.

3 PBV

The stock's PBV ratio (1.34x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

4 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

5 ROE

The stock's ROE indicates a negative return (-18.14%) on shareholders' equity, suggesting poor financial performance.

6 ROA

The stock's ROA (-11.56%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

9 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

10 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-13) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Psychemedics Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Psychemedics Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Psychemedics Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Psychemedics Corporation Revenue
Year Revenue Growth
1988 100.000
1989 300.000 66.67%
1990 1.700.000 82.35%
1991 2.500.000 32%
1992 4.000.000 37.5%
1993 6.600.000 39.39%
1994 8.700.000 24.14%
1995 10.100.000 13.86%
1996 12.200.000 17.21%
1997 15.400.000 20.78%
1998 17.700.000 12.99%
1999 19.600.000 9.69%
2000 19.219.700 -1.98%
2001 15.730.106 -22.18%
2002 16.068.130 2.1%
2003 15.995.256 -0.46%
2004 18.937.111 15.53%
2005 21.388.513 11.46%
2006 23.425.090 8.69%
2007 24.568.824 4.66%
2008 22.948.604 -7.06%
2009 16.954.994 -35.35%
2010 20.108.862 15.68%
2011 24.089.608 16.52%
2012 25.223.534 4.5%
2013 26.870.297 6.13%
2014 29.204.818 7.99%
2015 26.975.406 -8.26%
2016 38.980.000 30.8%
2017 39.701.000 1.82%
2018 42.674.000 6.97%
2019 37.678.000 -13.26%
2020 21.360.000 -76.4%
2021 24.909.000 14.25%
2022 25.240.000 1.31%
2023 22.816.000 -10.62%
2023 22.098.000 -3.25%
2024 18.912.000 -16.85%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Psychemedics Corporation Research and Development Expenses
Year Research and Development Expenses Growth
1988 0
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 400.000 100%
1995 400.000 0%
1996 400.000 0%
1997 400.000 0%
1998 500.000 20%
1999 500.000 0%
2000 475.700 -5.11%
2001 608.186 21.78%
2002 358.095 -69.84%
2003 305.683 -17.15%
2004 329.419 7.21%
2005 335.769 1.89%
2006 444.532 24.47%
2007 489.007 9.09%
2008 474.622 -3.03%
2009 467.435 -1.54%
2010 481.433 2.91%
2011 607.408 20.74%
2012 825.518 26.42%
2013 825.102 -0.05%
2014 1.348.496 38.81%
2015 1.631.664 17.35%
2016 1.415.000 -15.31%
2017 1.357.000 -4.27%
2018 1.551.000 12.51%
2019 1.567.000 1.02%
2020 1.280.000 -22.42%
2021 1.130.000 -13.27%
2022 1.326.000 14.78%
2023 1.100.000 -20.55%
2023 1.144.000 3.85%
2024 756.000 -51.32%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Psychemedics Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
1988 0
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 3.700.000 100%
1996 4.400.000 15.91%
1997 5.900.000 25.42%
1998 6.400.000 7.81%
1999 7.100.000 9.86%
2000 7.419.148 4.3%
2001 6.983.709 -6.24%
2002 6.755.217 -3.38%
2003 6.126.464 -10.26%
2004 5.787.441 -5.86%
2005 5.914.249 2.14%
2006 6.048.136 2.21%
2007 7.048.551 14.19%
2008 4.520.074 -55.94%
2009 3.596.774 -25.67%
2010 4.195.998 14.28%
2011 3.948.706 -6.26%
2012 3.946.844 -0.05%
2013 4.157.597 5.07%
2014 4.474.654 7.09%
2015 4.560.684 1.89%
2016 4.965.000 8.14%
2017 5.642.000 12%
2018 6.430.000 12.26%
2019 7.221.000 10.95%
2020 6.095.000 -18.47%
2021 6.126.000 0.51%
2022 5.857.000 -4.59%
2023 8.800.000 33.44%
2023 7.192.000 -22.36%
2024 6.364.000 -13.01%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Psychemedics Corporation EBITDA
Year EBITDA Growth
1988 -2.000.000
1989 -1.000.000 -100%
1990 -1.900.000 47.37%
1991 -1.200.000 -58.33%
1992 -400.000 -200%
1993 1.300.000 130.77%
1994 2.000.000 35%
1995 1.400.000 -42.86%
1996 2.500.000 44%
1997 3.200.000 21.88%
1998 3.700.000 13.51%
1999 4.800.000 22.92%
2000 3.244.691 -47.93%
2001 1.590.699 -103.98%
2002 2.941.598 45.92%
2003 2.809.927 -4.69%
2004 4.850.893 42.07%
2005 6.734.031 27.96%
2006 7.850.608 14.22%
2007 7.486.165 -4.87%
2008 5.038.202 -48.59%
2009 2.584.292 -94.95%
2010 4.699.374 45.01%
2011 6.170.470 23.84%
2012 4.935.688 -25.02%
2013 5.706.365 13.51%
2014 4.689.641 -21.68%
2015 1.471.376 -218.72%
2016 10.110.000 85.45%
2017 8.157.000 -23.94%
2018 7.610.000 -7.19%
2019 2.998.000 -153.84%
2020 -6.066.000 149.42%
2021 209.000 3002.39%
2022 -1.083.000 119.3%
2023 -4.428.000 75.54%
2023 -251.000 -1664.14%
2024 -940.000 73.3%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Psychemedics Corporation Gross Profit
Year Gross Profit Growth
1988 -200.000
1989 -1.000.000 80%
1990 700.000 242.86%
1991 1.100.000 36.36%
1992 2.400.000 54.17%
1993 4.200.000 42.86%
1994 5.400.000 22.22%
1995 5.900.000 8.47%
1996 7.700.000 23.38%
1997 10.000.000 23%
1998 11.200.000 10.71%
1999 12.400.000 9.68%
2000 10.324.552 -20.1%
2001 7.915.087 -30.44%
2002 9.049.310 12.53%
2003 8.370.083 -8.11%
2004 10.447.913 19.89%
2005 12.576.327 16.92%
2006 14.055.833 10.53%
2007 14.676.598 4.23%
2008 13.350.089 -9.94%
2009 9.609.978 -38.92%
2010 12.041.633 20.19%
2011 14.472.623 16.8%
2012 14.251.648 -1.55%
2013 15.394.034 7.42%
2014 15.138.166 -1.69%
2015 12.716.941 -19.04%
2016 21.450.000 40.71%
2017 19.822.000 -8.21%
2018 20.618.000 3.86%
2019 16.444.000 -25.38%
2020 4.886.000 -236.55%
2021 10.264.000 52.4%
2022 9.291.000 -10.47%
2023 8.364.000 -11.08%
2023 8.413.000 0.58%
2024 6.208.000 -35.52%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Psychemedics Corporation Net Profit
Year Net Profit Growth
1988 -1.800.000
1989 -1.000.000 -80%
1990 -2.100.000 52.38%
1991 -1.500.000 -40%
1992 -500.000 -200%
1993 1.000.000 150%
1994 1.800.000 44.44%
1995 1.600.000 -12.5%
1996 2.500.000 36%
1997 2.500.000 0%
1998 2.400.000 -4.17%
1999 2.300.000 -4.35%
2000 1.698.598 -35.41%
2001 232.525 -630.5%
2002 1.255.700 81.48%
2003 1.218.270 -3.07%
2004 2.763.783 55.92%
2005 4.048.513 31.73%
2006 4.902.201 17.41%
2007 4.483.687 -9.33%
2008 2.968.789 -51.03%
2009 1.527.295 -94.38%
2010 2.613.720 41.57%
2011 3.489.283 25.09%
2012 2.979.629 -17.1%
2013 3.805.210 21.7%
2014 3.206.081 -18.69%
2015 1.511.176 -112.16%
2016 6.678.000 77.37%
2017 6.121.000 -9.1%
2018 4.584.000 -33.53%
2019 1.542.000 -197.28%
2020 -3.859.000 139.96%
2021 -665.000 -480.3%
2022 -1.084.000 38.65%
2023 -8.396.000 87.09%
2023 -4.154.000 -102.12%
2024 -3.308.000 -25.57%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Psychemedics Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1988 -1
1989 0 0%
1990 -1 0%
1991 0 0%
1992 0 0%
1993 1 0%
1994 2 100%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 1 0%
2005 1 0%
2006 1 0%
2007 1 0%
2008 1 0%
2009 0 0%
2010 1 0%
2011 1 0%
2012 1 0%
2013 1 0%
2014 1 0%
2015 0 0%
2016 1 100%
2017 1 0%
2018 1 0%
2019 0 0%
2020 -1 0%
2021 0 0%
2022 0 0%
2023 -1 100%
2023 -1 0%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Psychemedics Corporation Free Cashflow
Year Free Cashflow Growth
1991 -1.200.000
1992 -900.000 -33.33%
1993 100.000 1000%
1994 1.700.000 94.12%
1995 600.000 -183.33%
1996 1.700.000 64.71%
1997 700.000 -142.86%
1998 3.100.000 77.42%
1999 2.400.000 -29.17%
2000 2.429.022 1.19%
2001 1.885.733 -28.81%
2002 2.230.273 15.45%
2003 1.811.214 -23.14%
2004 1.891.617 4.25%
2005 4.061.544 53.43%
2006 4.348.130 6.59%
2007 4.474.778 2.83%
2008 3.342.959 -33.86%
2009 2.364.155 -41.4%
2010 2.477.437 4.57%
2011 2.576.411 3.84%
2012 751.308 -242.92%
2013 4.193.785 82.09%
2014 -3.351.147 225.14%
2015 2.781.681 220.47%
2016 7.175.000 61.23%
2017 7.900.000 9.18%
2018 6.605.000 -19.61%
2019 2.576.000 -156.41%
2020 -5.074.000 150.77%
2021 232.000 2287.07%
2022 4.703.000 95.07%
2023 0 0%
2023 -1.639.000 100%
2024 81.000 2123.46%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Psychemedics Corporation Operating Cashflow
Year Operating Cashflow Growth
1991 -1.100.000
1992 -500.000 -120%
1993 500.000 200%
1994 2.200.000 77.27%
1995 2.000.000 -10%
1996 2.400.000 16.67%
1997 2.100.000 -14.29%
1998 5.000.000 58%
1999 2.900.000 -72.41%
2000 3.205.367 9.53%
2001 2.466.217 -29.97%
2002 2.436.067 -1.24%
2003 2.072.831 -17.52%
2004 2.268.895 8.64%
2005 4.350.688 47.85%
2006 4.605.169 5.53%
2007 4.890.717 5.84%
2008 3.687.493 -32.63%
2009 2.399.582 -53.67%
2010 3.295.397 27.18%
2011 3.935.201 16.26%
2012 3.086.731 -27.49%
2013 5.951.547 48.14%
2014 4.457.233 -33.53%
2015 4.579.837 2.68%
2016 9.269.000 50.59%
2017 9.146.000 -1.34%
2018 7.929.000 -15.35%
2019 4.309.000 -84.01%
2020 -4.083.000 205.54%
2021 414.000 1086.23%
2022 4.890.000 91.53%
2023 0 0%
2023 -1.480.000 100%
2024 120.000 1333.33%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Psychemedics Corporation Capital Expenditure
Year Capital Expenditure Growth
1991 100.000
1992 400.000 75%
1993 400.000 0%
1994 500.000 20%
1995 1.400.000 64.29%
1996 700.000 -100%
1997 1.400.000 50%
1998 1.900.000 26.32%
1999 500.000 -280%
2000 776.345 35.6%
2001 580.484 -33.74%
2002 205.794 -182.07%
2003 261.617 21.34%
2004 377.278 30.66%
2005 289.144 -30.48%
2006 257.039 -12.49%
2007 415.939 38.2%
2008 344.534 -20.73%
2009 35.427 -872.52%
2010 817.960 95.67%
2011 1.358.790 39.8%
2012 2.335.423 41.82%
2013 1.757.762 -32.86%
2014 7.808.380 77.49%
2015 1.798.156 -334.24%
2016 2.094.000 14.13%
2017 1.246.000 -68.06%
2018 1.324.000 5.89%
2019 1.733.000 23.6%
2020 991.000 -74.87%
2021 182.000 -444.51%
2022 187.000 2.67%
2023 0 0%
2023 159.000 100%
2024 39.000 -307.69%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Psychemedics Corporation Equity
Year Equity Growth
1988 800.000
1989 700.000 -14.29%
1990 600.000 -16.67%
1991 2.700.000 77.78%
1992 2.600.000 -3.85%
1993 3.500.000 25.71%
1994 9.600.000 63.54%
1995 9.500.000 -1.05%
1996 14.300.000 33.57%
1997 16.700.000 14.37%
1998 15.900.000 -5.03%
1999 11.800.000 -34.75%
2000 8.726.170 -35.23%
2001 6.771.979 -28.86%
2002 6.343.733 -6.75%
2003 5.110.876 -24.12%
2004 6.234.049 18.02%
2005 8.894.564 29.91%
2006 11.503.505 22.68%
2007 13.877.931 17.11%
2008 10.559.888 -31.42%
2009 9.294.384 -13.62%
2010 9.747.513 4.65%
2011 11.034.629 11.66%
2012 11.222.669 1.68%
2013 12.277.125 8.59%
2014 12.836.556 4.36%
2015 11.673.530 -9.96%
2016 15.607.000 25.2%
2017 18.620.000 16.18%
2018 18.747.000 0.68%
2019 16.820.000 -11.46%
2020 12.512.000 -34.43%
2021 12.243.000 -2.2%
2022 10.771.000 -13.67%
2023 6.672.000 -61.44%
2023 7.429.000 10.19%
2024 5.741.000 -29.4%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Psychemedics Corporation Assets
Year Assets Growth
1988 1.000.000
1989 1.100.000 9.09%
1990 1.500.000 26.67%
1991 3.300.000 54.55%
1992 3.000.000 -10%
1993 4.400.000 31.82%
1994 10.300.000 57.28%
1995 10.200.000 -0.98%
1996 15.700.000 35.03%
1997 18.900.000 16.93%
1998 18.700.000 -1.07%
1999 14.200.000 -31.69%
2000 11.057.897 -28.42%
2001 9.108.383 -21.4%
2002 8.082.674 -12.69%
2003 7.266.991 -11.22%
2004 8.433.636 13.83%
2005 11.145.026 24.33%
2006 13.260.903 15.96%
2007 15.560.768 14.78%
2008 12.627.786 -23.23%
2009 10.602.426 -19.1%
2010 11.766.321 9.89%
2011 13.800.852 14.74%
2012 14.120.618 2.26%
2013 16.549.816 14.68%
2014 24.077.709 31.26%
2015 22.362.968 -7.67%
2016 25.032.000 10.66%
2017 26.508.000 5.57%
2018 24.974.000 -6.14%
2019 27.531.000 9.29%
2020 24.003.000 -14.7%
2021 21.552.000 -11.37%
2022 18.732.000 -15.05%
2023 13.270.000 -41.16%
2023 14.104.000 5.91%
2024 10.113.000 -39.46%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Psychemedics Corporation Liabilities
Year Liabilities Growth
1988 200.000
1989 400.000 50%
1990 900.000 55.56%
1991 600.000 -50%
1992 400.000 -50%
1993 900.000 55.56%
1994 700.000 -28.57%
1995 700.000 0%
1996 1.400.000 50%
1997 2.200.000 36.36%
1998 2.800.000 21.43%
1999 2.400.000 -16.67%
2000 2.331.727 -2.93%
2001 2.336.404 0.2%
2002 1.738.941 -34.36%
2003 2.156.115 19.35%
2004 2.199.587 1.98%
2005 2.250.462 2.26%
2006 1.757.398 -28.06%
2007 1.682.837 -4.43%
2008 2.067.898 18.62%
2009 1.308.042 -58.09%
2010 2.018.808 35.21%
2011 2.766.223 27.02%
2012 2.897.949 4.55%
2013 4.272.691 32.18%
2014 11.241.153 61.99%
2015 10.689.438 -5.16%
2016 9.425.000 -13.42%
2017 7.888.000 -19.49%
2018 6.227.000 -26.67%
2019 10.711.000 41.86%
2020 11.491.000 6.79%
2021 9.309.000 -23.44%
2022 7.961.000 -16.93%
2023 6.598.000 -20.66%
2023 6.675.000 1.15%
2024 4.372.000 -52.68%

Psychemedics Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3.57
Net Income per Share
-0.78
Price to Earning Ratio
-2.95x
Price To Sales Ratio
0.65x
POCF Ratio
-20.71
PFCF Ratio
-18.54
Price to Book Ratio
2.34
EV to Sales
0.67
EV Over EBITDA
-8.42
EV to Operating CashFlow
-21.41
EV to FreeCashFlow
-19.14
Earnings Yield
-0.34
FreeCashFlow Yield
-0.05
Market Cap
0,01 Bil.
Enterprise Value
0,01 Bil.
Graham Number
4.17
Graham NetNet
-0.11

Income Statement Metrics

Net Income per Share
-0.78
Income Quality
0.14
ROE
-0.7
Return On Assets
-0.3
Return On Capital Employed
-0.48
Net Income per EBT
1.01
EBT Per Ebit
1.01
Ebit per Revenue
-0.14
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0.36
Research & Developement to Revenue
0.05
Stock Based Compensation to Revenue
0.06
Gross Profit Margin
0.38
Operating Profit Margin
-0.14
Pretax Profit Margin
-0.15
Net Profit Margin
-0.15

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.18
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.11
Free CashFlow per Share
-0.12
Capex to Operating CashFlow
-0.12
Capex to Revenue
0
Capex to Depreciation
0.03
Return on Invested Capital
-0.6
Return on Tangible Assets
-0.45
Days Sales Outstanding
53.98
Days Payables Outstanding
18.64
Days of Inventory on Hand
0
Receivables Turnover
6.76
Payables Turnover
19.58
Inventory Turnover
0
Capex per Share
0.01

Balance Sheet

Cash per Share
0,25
Book Value per Share
0,99
Tangible Book Value per Share
0.99
Shareholders Equity per Share
0.99
Interest Debt per Share
0.32
Debt to Equity
0.33
Debt to Assets
0.18
Net Debt to EBITDA
-0.26
Current Ratio
1.6
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
5833000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.14

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Psychemedics Corporation Dividends
Year Dividends Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 1 0%
2008 1 0%
2009 1 0%
2010 0 0%
2011 0 0%
2012 1 0%
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Psychemedics Corporation Profile

About Psychemedics Corporation

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.

CEO
Mr. Brian Hullinger
Employee
116
Address
289 Great Road
Acton, 01720

Psychemedics Corporation Executives & BODs

Psychemedics Corporation Executives & BODs
# Name Age
1 Mr. Brian Hullinger
President, Chief Executive Officer & Director
70
2 Ms. Shannon Shoemaker
Vice President & Chief Revenue Officer
70
3 Ms. Daniella Mehalik
Vice President of Finance
70
4 Mr. Michael Weisenhoff
Principal Financial & Accounting Manager
70
5 Mr. Patrick J. Kinney Jr.
Secretary
70
6 Dr. Werner A. Baumgartner Ph.D.
Founder
70
7 Ms. Annette Baumgartner
Founder
70

Psychemedics Corporation Competitors